P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors
Andrea Romagnani1, Elsa Rottoli1,2, Emilia Maria Cristina Mazza3
1Institute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona, Switzerland.
Abstract:
Extracellular ATP (eATP) is a signaling molecule that variably affects all cells of the immune system either directly or after hydrolysis to adenosine. Although eATP is virtually absent in the interstitium of normal tissues, it can be present in the hundreds of micromolar range in tumors, a concentration compatible with activation of the ATP-gated ionotropic P2X7 receptor. Here, we show that P2X7 activity in tumor-infiltrating lymphocytes (TIL) induces cellular senescence and limits tumor suppression. P2X7 stimulation affected cell cycling of effector T cells and resulted in generation of mitochondrial reactive oxygen species and p38 MAPK-dependent upregulation of cyclin-dependent kinase inhibitor 1A (Cdkn1a, encoding for p21Waf1/Cip1). Lack of P2X7 promoted a transcriptional signature that correlated with enhanced cytotoxic T-cell response in human solid tumors. In mice, transfer of tumor-specific T cells with deletion of P2rx7 significantly reduced tumor growth and extended survival. Collectively, these findings uncover a purinergic checkpoint that can be targeted to improve the efficacy of cancer immunotherapy strategies. SIGNIFICANCE: These findings suggest that the purinergic checkpoint P2X7 may be targeted to enhance T-cell-mediated cancer immunotherapy and improve T effector cell accumulation in the tumor microenvironment. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/18/3906/F1.large.jpg.
Insights
Extracellular ATP (eATP) activates the P2X7 receptor on tumor-infiltrating lymphocytes, inducing senescence and limiting tumor suppression. Blocking P2X7 enhances anti-tumor T-cell responses, improving cancer immunotherapy efficacy.
Area of Science:
- Immunology
- Cancer Biology
- Molecular Signaling
Background:
- Extracellular ATP (eATP) is a signaling molecule influencing immune cells.
- High eATP concentrations in tumors can activate the P2X7 receptor.
- The role of P2X7 in tumor-infiltrating lymphocytes (TIL) was previously unclear.
Purpose of the Study:
- To investigate the role of P2X7 receptor activity in TIL.
- To determine the impact of P2X7 on T-cell function and tumor suppression.
- To explore P2X7 as a potential target for cancer immunotherapy.
Main Methods:
- Analysis of P2X7 activity in TIL.
- Assessment of T-cell cycling, mitochondrial ROS generation, and p38 MAPK signaling.
- Gene expression profiling in human tumors.
- Tumor growth and survival studies in mice with P2rx7-deleted T cells.
Main Results:
- P2X7 activation in TIL induced cellular senescence and limited tumor suppression.
- P2X7 stimulation affected effector T-cell cycling and upregulated p21Waf1/Cip1.
- Lack of P2X7 correlated with enhanced cytotoxic T-cell response and reduced tumor growth in mice.
Conclusions:
- P2X7 acts as a purinergic checkpoint in the tumor microenvironment.
- Targeting P2X7 can enhance T-cell-mediated anti-tumor immunity.
- Inhibiting P2X7 may improve cancer immunotherapy outcomes by promoting T-cell accumulation.
Related Concept Videos
Abnormal Proliferation
Tumor Immunotherapy
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
The Tumor Microenvironment
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...


